Research Paper Volume 12, Issue 10 pp 9500—9514

MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA

Figure 6. High miR-16-5p levels inhibit osteogenic differentiation in osteoporosis patients and hMSCs. (A) QRT-PCR analysis of miR-16-5p levels in postmenopausal patients with or without osteoporosis (n=10 per group). (B) QRT-PCR analysis of miR-16-5p levels in control hMSCs and hMSCs transfected with agomiR-NC, agomiR-16-5p, antagomiR-NC, and antagomiR-16-5p is shown. (C) QRT-PCR analysis shows the relative expression of osteogenic marker genes, ALP, OCN and RUNX2, in control hMSCs and hMSCs transfected with agomiR-NC, agomiR-16-5p, antagomiR-NC, and antagomiR-16-5p. (D, E) Alizarin red staining shows calcium deposition in control hMSCs and hMSCs transfected with agomiR-NC, agomiR-16-5p, antagomiR-NC, and antagomiR-16-5p for 21 days. Scale bar = 10 mm. Note: The data are represented as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.